Edition:
United Kingdom

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.64USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$2.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
581,352
52-wk High
$8.68
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $27.98
Shares Outstanding(Mil.): 8.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

04 Jan 2018

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update

14 Nov 2017

BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1

* Celsion files immunotherapy clinical protocol for the evaluation of Gen-1 to treat newly diagnosed ovarian cancer

13 Nov 2017

BRIEF-CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING

* CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK

27 Oct 2017

BRIEF-Celsion provides update on Thermodox in liver cancer study

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

27 Sep 2017

BRIEF-Celsion Corp Q2 loss per share $0.79

* Celsion corporation reports second quarter 2017 financial results and provides business update

15 Aug 2017

BRIEF-Celsion Corp says DMC completes mid-study review of phase III thermodox optima study

* Data monitoring committee completes mid-study review of Celsion's phase III thermodox optima study in primary liver cancer

07 Aug 2017

BRIEF-Celsion Corporation to delist from Tel Aviv stock exchange

* Celsion Corporation to delist from Tel Aviv stock exchange Source text for Eikon: Further company coverage:

05 Aug 2017

BRIEF-Celsion Corp announces data from ovation study

* Celsion corp - ‍announces latest translational data from ovation study in newly diagnosed advanced ovarian cancer patients​ Source text for Eikon: Further company coverage:

02 Aug 2017

Earnings vs. Estimates